Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is also effective in C3 ...

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals ALNY. New drug Fabhalta for PNH and IgAN ...

Fabhalta, inalumab, and pelacarsen. Among these, pelacarsen stands out as a potential game-changer, with its readout expected in the first half of 2026. This drug could give Novartis a first-mover ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...